Parkinson’s disease is one of the main reasons for neurological consultation in Spain. Due to the nature of the disease, it impacts patients, families, and caregivers. Parkinson’s disease is a degenerative disease with no cure, although second-line therapies have recently improved the quality of life of patients in advanced stages. The aim of this study was to analyse the costs of the following therapies: deep brain stimulation (DBS), continuous duodenal levodopa/carbidopa infusion (CDLCI), and continuous subcutaneous apomorphine infusion (CSAI). The methodology used was based on real-world data obtained from an integrated healthcare organization in the Basque Country from 2016 to 2018. This bottom-up retrospective approach only took into account the healthcare perspective. The results revealed the annual cost over 3 years and the projected cost for an additional 2 years. The total costs for 5 years of treatment were as follows: €53,217 for DBS, €208,163 for CDLCI, and €170,591 for CSAI. These costs are in line with those found in the available literature on the subject. Additionally, the analysis provided details of the different costs incurred during intervention with the therapies and compared the costs to those reported in other studies.

中文翻译：

---

帕金森氏病的直接费用：二线疗法的实际数据研究。

帕金森氏病是西班牙进行神经科咨询的主要原因之一。由于疾病的性质，它会影响患者，家庭和护理人员。帕金森氏病是一种无法治愈的退行性疾病，尽管最近二线疗法已改善了晚期患者的生活质量。这项研究的目的是分析以下疗法的费用：深部脑刺激（DBS），十二指肠左旋多巴/卡比多巴连续输注（CDLCI）和皮下阿扑吗啡持续输注（CSAI）。使用的方法是基于2016年至2018年从巴斯克地区一家综合医疗机构获得的真实数据。这种自下而上的回顾性方法仅考虑了医疗角度。结果显示了3年的年度成本以及另外2年的预计成本。五年治疗的总费用如下：星展银行为53,217欧元，CDLCI为208,163欧元，CSAI为170,591欧元。这些费用与有关该主题的现有文献中的费用一致。此外，分析还提供了干预治疗期间产生的不同费用的详细信息，并将这些费用与其他研究报告的费用进行了比较。